NASDAQ$RLMD

Relmada Therapeutics Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

RLMD Q3 2024 — n/d revenue, 0.72 EPS

Interim results are not necessarily indicative of the results. Relmada Therapeutics Inc reported Q3 2024 results. Diluted EPS came in at $0.72. Net income of $73.6M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Diluted EPS: $0.72.
  • Net income: $73.6M.
  • Filed on Form 10-Q (accession 0001213900-24-095398).

Headline financials

Total Revenue

$148K

Previous: -$51.7K+385.9%
EPS (adj)

-$0.72

Previous: -$0.73+1.4%
Capital Expenditures

$0.00

Previous: $0.00
Free Cash Flow

-$21.7M

Previous: -$22M+1.3%
Net Income

-$21.7M

Previous: -$22M+1.3%
Operating Income

-$23M

Previous: -$22.7M-1.4%
Gross Profit

$148K

Previous: -$51.7K+385.9%
R&D Expense

$11.1M

Previous: $10.5M+6.6%
Stock-Based Comp

$7.95M

Previous: $11.4M-30.2%

Revenue & EPS history

Relmada · Revenue · Quarterly

$148K

Q3 2024-385.9%vs Q3 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-1.6%

Avg return

Earnings day

-1.4%

Avg return

5 days after

+3.2%

Avg return

30 days after

35%

15 / 43 earnings

Positive

+10.8%

Q4 2024

Best reaction

-29.0%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-2.0%-12.5%
Q1 2026+1.2%-6.1%-11.4%
Q3 2025+1.8%+7.7%+4.6%
Q2 2025-2.5%-5.6%+174.1%
Q1 2025+6.6%+33.4%+53.6%
Q4 2024+10.8%-5.1%+33.2%
Q3 2024-3.5%-2.9%-86.5%
Q2 2024-29.0%-29.0%-25.9%
Q1 2024-0.5%-7.6%-22.8%
Q4 2023-19.6%-12.0%-22.1%
Q3 2023-2.0%-7.5%-16.1%
Q2 2023+3.0%+17.4%+34.5%
Q1 2023-9.2%-10.7%-19.0%
Q4 2022-3.0%+4.3%+12.8%
Q3 2022+10.4%+2.3%-53.5%
Q2 2022-0.7%-2.8%+8.9%
Q1 2022-12.4%-18.5%-20.1%
Q4 2021+7.5%+10.4%+4.9%
Q3 2021-8.2%-12.0%-24.4%
Q2 2021+4.8%+0.6%+13.6%
Q1 2021-4.1%+0.0%-10.9%
Q4 2020-10.4%-7.4%+4.3%
Q3 2020+0.0%+8.3%+0.9%
Q2 2020-0.3%+7.7%+0.0%
Q1 2020+9.6%+8.5%+12.6%
Q4 2019-0.1%-1.7%+19.7%
Q3 2019-3.0%-5.1%+29.9%
Q2 2019-4.0%-8.5%+106.8%
Q1 2019+0.0%+1.7%+13.9%
Q3 2018+5.1%+2.6%-1.7%
Q1 2018-5.0%+5.3%-13.3%
Q2 2018+0.0%-2.1%-3.5%
Q4 2017+4.7%+4.7%-11.0%
Q3 2017-2.0%-2.0%-20.6%
Q2 2017-8.6%-4.8%-32.9%
Q1 2017+7.4%+0.0%-19.3%
Q3 2016-17.8%
Q2 2016+2.7%
Q1 2016-1.1%
Q3 2015-2.5%
Q2 2014+4.2%
Q3 2014-4.6%
Q1 2015+5.9%
Q4 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2012
Q3 2012
Q2 2012
Q1 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro